Free Trial

Oruka Therapeutics (ORKA) Stock Price, News & Analysis

Oruka Therapeutics logo
$15.12 +0.72 (+5.00%)
As of 09:44 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Oruka Therapeutics Stock (NASDAQ:ORKA)

Key Stats

Today's Range
$14.10
$14.99
50-Day Range
$10.90
$15.50
52-Week Range
$5.49
$52.32
Volume
181,811 shs
Average Volume
136,530 shs
Market Capitalization
$566.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.38
Consensus Rating
Buy

Company Overview

Oruka Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

ORKA MarketRank™: 

Oruka Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 603rd out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oruka Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Oruka Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Oruka Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Oruka Therapeutics are expected to grow in the coming year, from ($3.41) to ($2.92) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oruka Therapeutics is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oruka Therapeutics is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oruka Therapeutics has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for ORKA.
  • Dividend Yield

    Oruka Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Oruka Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ORKA.
  • News Sentiment

    Oruka Therapeutics has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 22 news articles for Oruka Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for ORKA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 7 people have added Oruka Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oruka Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    24.69% of the stock of Oruka Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    56.44% of the stock of Oruka Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Oruka Therapeutics' insider trading history.
Receive ORKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oruka Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ORKA Stock News Headlines

HC Wainwright Issues Negative Estimate for ORKA Earnings
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
HC Wainwright Reiterates Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)
Oruka Therapeutics (ORKA) Receives a Buy from H.C. Wainwright
Q3 EPS Estimate for Oruka Therapeutics Lowered by Analyst
See More Headlines

ORKA Stock Analysis - Frequently Asked Questions

Oruka Therapeutics' stock was trading at $19.39 on January 1st, 2025. Since then, ORKA shares have decreased by 23.7% and is now trading at $14.79.

Oruka Therapeutics, Inc. (NASDAQ:ORKA) announced its quarterly earnings data on Monday, August, 11th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.02.

Oruka Therapeutics' top institutional investors include Braidwell LP (4.07%), Franklin Resources Inc. (2.71%), Geode Capital Management LLC (1.89%) and Affinity Asset Advisors LLC (1.61%).
View institutional ownership trends
.

Shares of ORKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oruka Therapeutics investors own include Astria Therapeutics (ATXS), Aldeyra Therapeutics (ALDX), Black Diamond Therapeutics (BDTX), Energy Transfer (ET), Heron Therapeutics (HRTX), Skye Bioscience (SKYE) and NuScale Power (SMR).

Company Calendar

Last Earnings
8/11/2025
Today
8/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORKA
Previous Symbol
NASDAQ:ORKA
CIK
907654
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$49.00
Low Price Target
$20.00
Potential Upside/Downside
+173.0%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.81)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$83.72 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-26.26%
Return on Assets
-24.16%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
27.42
Quick Ratio
27.42

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.10 per share
Price / Book
1.63

Miscellaneous

Outstanding Shares
37,450,000
Free Float
28,204,000
Market Cap
$553.89 million
Optionable
N/A
Beta
-0.35
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:ORKA) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners